Hangzhou Tigermed Consulting (300347.SZ) plans to sell all the equity held by Taige Holdings in Lixin Pharmaceutical for an estimated price of approximately 34.11 million US dollars.

Hangzhou Tigermed Consulting (300347.SZ) announced that Lixin Pharmaceutical Technology (Shanghai) Co., Ltd. (referred to as "Lixin Pharmaceuticals") plans to transfer 95.09% of its equity (of which the equity held by the company's investment platform, Taige Equity, is 3.41%) to Sinopharm Pharmaceutical Investment (Beijing) Group Co., Ltd. (referred to as "Sinopharm Pharmaceutical"). As a shareholder of Lixin Pharmaceuticals, the company agrees to the sale arrangement of the target company and plans to transfer all of Taige Equity's shares in Lixin Pharmaceuticals directly to the buyer as consideration for approximately $34.11 million, and sign the relevant transaction documents. It is reported that the sale of the equity of the affiliated company is beneficial for the company to increase its cash income and supplement the company's cash flow.